IP Library Granted Patent US 10,668,230
Granted Patent B2
US 10,668,230 · App. 12/176,108 · Granted Jun 2, 2020

Particle dispersion chamber for nasal nebulizer

Inventor: Marc Giroux (Lynnwood, WA)
Assignee: Kurve Technology, Inc.
A61M15/0028A61M11/00A61M11/001A61M15/0008A61M15/0086A61M16/06A61M16/0611A61M2206/16A61M2210/0618
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,668,230
App. No.
12/176,108
Granted
Jun 2, 2020
Kind
B2
Abstract

A nebulizer and a method of breathing using the nebulizer is described. The nebulizer and breathing techniques are capable of delivering medicament into the sinus cavity of a user.

Claims (19)

1. A method for intranasal drug delivery, comprising:

aerosolizing a medicament to provide aerosolized medicament particles in a size range of 2 to 50 microns;

imparting an unobstructed continuous vortical flow to the aerosolized medicament particles; and

directing the medicament particles through a nasal adapter and into a nasal cavity, while still in the unobstructed continuous vortical flow, to provide for at least one of topical drug delivery sufficiently deep within the nasal cavity to provide for penetration into at least an ethmoid and/or sphenoid paranasal sinus, or systemic drug delivery sufficiently deep within the nasal cavity to provide for penetration into at least the ethmoid and/or sphenoid paranasal sinus; wherein imparting the unobstructed vortical flow to the aerosolized medicament particles comprises exposing the aerosolized medicament particles to a plurality of directed air outputs from curved tubes along an outer surface of the particle dispersion chamber, the curved tubes extending into the particle dispersion chamber.

2. The method of claim 1 , wherein aerosolizing comprises aerosolizing a medicament to provide aerosolized medicament particles in a size range of 15 to 35 microns.

3. The method of claim 2 , wherein aerosolizing comprises aerosolizing a medicament to provide aerosolized medicament particles in a size range of 20 to 30 microns.

4. The method of claim 1 , wherein aerosolizing comprises aerosolizing a medicament to provide aerosolized medicament particles in a size range of 2 to 15 microns.

5. The method of any one of claims 1 through 4 , wherein imparting the unobstructed continuous vortical flow to the aerosolized medicament particles comprises passing the aerosolized medicament particles through an unobstructed particle dispersion channel prior to nasal delivery.

6. The method of claim 5 , wherein imparting the unobstructed continuous vortical flow to the aerosolized medicament particles comprises exposing the aerosolized medicament particles to a plurality of directed air outputs configured to impart the vortical flow to the aerosolized medicament particles prior to nasal delivery.

7. The method of claim 1 , wherein imparting the unobstructed continuous vortical flow to the aerosolized medicament particles comprises exposing the aerosolized medicament particles to a plurality of directed air outputs from a corresponding plurality of curved channels having individual flow paths along an outer surface of or in a wall of the particle dispersion chamber and extending into the particle dispersion chamber, or from a corresponding plurality of directional output nozzles in the particle dispersion chamber, to impart the vortical flow to the aerosolized medicament particles prior to nasal delivery.

8. A method for intranasal drug delivery, comprising:

introducing a compressed fluid from a nebulizing pressure feed through a compressor channel into a nebulizing chamber, the compressor channel channeling compressed fluid;

introducing a medicament into the nebulizing chamber along with the compressed fluid, thereby aerosolizing the medicament and forming aerosolized medicament particles in a size range of 2 to 50 microns;

directly communicating the aerosolized medicament particles from the nebulizing chamber into a particle dispersion chamber having a particle input end and an output opening and an internal channel between the particle input end and the output opening, the internal channel having a continuous cross-sectional area from the particle input end to the output opening;

providing an output fluid through fluid outputs communicating with the internal channel and thereby directing output forward and imparting an unobstructed continuous vortical flow to the aerosolized medicament particles exiting the dispersion chamber output opening and entering a nasal adapter, wherein the fluid outputs comprise a plurality of directed air outputs from curved tubes along an outer surface of the particle dispersion chamber, the curved tubes extending into the particle dispersion chamber; and

directing the medicament particles through the nasal adapter and into a nasal cavity, while still in the unobstructed continuous vortical flow, to provide for at least one of topical drug delivery sufficiently deep within the nasal cavity to provide for penetration into at least an ethmoid and/or sphenoid paranasal sinus, or systemic drug delivery sufficiently deep within the nasal cavity to provide for penetration into at least the ethmoid and/or sphenoid paranasal sinus.

9. The method of claim 8 , wherein the compressed fluid comprises air or another compressible gas.

10. The method of claim 8 , wherein introducing the medicament into the nebulizing chamber comprises introducing multiple doses of the medicament into a multi-dose compartment.

11. The method of claim 8 , wherein imparting the unobstructed continuous vortical flow to the aerosolized medicament particles comprises exposing the aerosolized medicament particles to a plurality of directed air outputs from a corresponding plurality of curved channels having individual flow paths along an outer surface of or in a wall of the particle dispersion chamber and extending into the particle dispersion chamber, or from a corresponding plurality of directional output nozzles in the particle dispersion chamber, to impart the vortical flow to the aerosolized medicament particles prior to nasal delivery.

Assignments (6)
CORRECTIVE ASSIGNMENT TO CORRECT THE NATURE OF CONVEYANCE FROM "ASSIGNMENT" TO "NUNC PRO TUNC ASSIGNMENT" PREVIOUSLY RECORDED AT REEL: 060611 FRAME: 0142. ASSIGNOR(S) HEREBY CONFIRMS THE NUNC PRO TUNC ASSIGNMENT. Recorded Oct 3, 2022
From: KURVE TECHNOLOGY, INC.
To: SAVILE THERAPEUTICS, INC.
Reel/Frame 061592/0947 →
MERGER Recorded Sep 19, 2022
From: SAVILE THERAPEUTICS, INC.
To: KURVE THERAPEUTICS, INC.
Reel/Frame 061469/0911 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2022
From: KURVE TECHNOLOGY, INC.
To: SAVILE THERAPEUTICS, INC.
Reel/Frame 060611/0142 →
SECURITY INTEREST Recorded Mar 7, 2016
From: KURVE TECHNOLOGY, INC.
To: KVEST, LLC
Reel/Frame 037910/0456 →
SECURITY INTEREST Recorded Dec 23, 2009
From: KURVE TECHNOLOGY, INC.
To: CNS CORPORATION
Reel/Frame 023699/0083 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2009
From: GIROUX, MARC
To: KURVE TECHNOLOGY, INC.
Reel/Frame 022333/0415 →
Continuity (3)
Continuation 10435401 · May 9, 2003
Provisional Application 60379428 · May 9, 2002
Related Publication 20090159080A1 · Jun 25, 2009
Cited By (1)
US 12,697,446